Claims for Patent: 9,388,235

Summary for Patent: 9,388,235

Title:	Methods and compositions for the treatment of antibody mediated neuropathies
Abstract:	The use of a therapeutic capable of inhibiting complement, e.g., an anti-C5 antibody, to treat antibody mediated neuropathies is disclosed.
Inventor(s):	Halstead; Susan (Glasgow, GB), Willison; Hugh (Glasgow, GB), Rother; Russell P. (Oklahoma City, OK)
Assignee:	Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:	12/439,070
Patent Claims:	1. A method of treating a mammal having Guillain-Barre syndrome, said method comprising administering to the mammal a therapeutically effective amount of a complement cascade inhibitor, wherein said inhibitor is an antibody or antigen-binding fragment thereof which specifically binds: (i) to complement component C5 and inhibits the cleavage of C5 into fragments C5a and C5b; and/or (ii) to C5b, wherein said antibody or antigen-binding fragment thereof inhibits membrane attack complex (MAC) formation. 2. The method of claim 1 wherein said mammal has the Miller Fisher variant of Guillain-Barre syndrome. 3. The method of claim 1 wherein said mammal is a human. 4. The method of claim 1 wherein said antibody or antigen-binding fragment thereof is at least one selected from the group consisting of: a polyclonal antibody, a monoclonal antibody or antigen-binding fragment thereof, a diabody, a chimerized or chimeric antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a deimmunized antibody or antigen-binding fragment thereof, a fully human antibody or antigen-binding fragment thereof, a single chain antibody, an Fv, an Fab, an Fab', and an F(ab').sub.2. 5. The method of claim 1 wherein said antibody is eculizumab. 6. The method of claim 1 wherein said antigen-binding fragment thereof is pexelizumab. 7. The method of claim 5 wherein said treating is chronic. 8. The method of claim 6 wherein said treating comprises treating an acute episode. 9. The method of claim 1 wherein said antibody or antigen-binding fragment thereof is formulated to be administrable to said mammal intravenously. 10. The method of claim 1 wherein said antibody or antigen-binding fragment thereof is formulated to be administrable to said mammal systemically. 11. The method of claim 1, wherein said antibody or antigen-binding fragment thereof is formulated to be administrable to said mammal locally. 12. The method of claim 1 wherein said treating results in decreased neural injury in said mammal. 13. The method of claim 1 wherein said treating results in decreased membrane attack complex (MAC) formation at presynaptic neuromuscular junctions. 14. The method of claim 1 wherein said treating restores a normal frequency of miniature endplate potentials. 15. The method of claim 1 wherein said treating restores synaptic transmission at the neuromuscular junctions. 16. The method of claim 1 wherein said treating inhibits loss of terminal integrity at the neuromuscular junctions.

Details for Patent 9,388,235

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	03/16/2007		2026-09-05